84395-93-7

Basic information

• Product Name: 1,2-Benzisoxazole-3-carboxaldehyde (9CI)
• Synonyms: 1,2-Benzisoxazole-3-carboxaldehyde (9CI)
• CAS NO: 84395-93-7
• Molecular Formula: C₈H₅NO₂
• Molecular Weight: 147.1308
• Product Categories: ALDEHYDE
• Mol File: 84395-93-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2-Benzisoxazole-3-carboxaldehyde (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzisoxazole-3-carboxaldehyde (9CI)(84395-93-7)
• EPA Substance Registry System: 1,2-Benzisoxazole-3-carboxaldehyde (9CI)(84395-93-7)

Safety Data

• Hazardous Substances Data: 84395-93-7(Hazardous Substances Data)

Usage

General Description

1,2-Benzisoxazole-3-carboxaldehyde (9CI) is a chemical compound that belongs to the benzisoxazole family. It is a colorless to light yellow liquid with a characteristic odor. This chemical is used in the synthesis of various pharmaceutical compounds, such as antihistamines and anti-inflammatory drugs. It is also used as a building block in the production of agrochemicals and dyes. Additionally, 1,2-Benzisoxazole-3-carboxaldehyde (9CI) has potential applications in the field of materials science, as it can be used in the synthesis of polymers and other high-performance materials. However, due to its hazardous nature, proper safety precautions should be taken when handling and storing this chemical.

Upstream product

• 1076-38-6 4-hydroxy[1]benzopyran-2-one 
• 4865-84-3 2-(benzo[d]isoxazol-3-yl)acetic acid 
• 22105-09-5 4‐hydroxycoumarin 
• 37924-67-7 α-bromo-1,2-benzisoxazole-3-acetic acid 
• 1196-29-8 2-hydroxyacetophenoneoxime 
• 54758-75-7 1-(2-hydroxyphenyl)ethanone O-acetyl oxime 
• 118-93-4 o-hydroxyacetophenone 
• 81981-84-2 C₁₄H₁₁ClN₂O₂S 
• 82897-94-7 (1,2-benzisoxazol-3-yl)methyl phenyl sulfoxide 
• 84395-94-8 (1,2-benzisoxazol-3-yl)(phenylthio)methyl acetate 
• 81981-86-4 3-phenylsulphinyliminomethyl-1,2-benzisoxazole 
• 75326-37-3 N-bromo-S-phenyl-S<(1,2-benzisoxazol-3-yl)methyl>sulfoximide 
• 75326-34-0 C₁₄H₁₁ClN₂O₂S 
• 37924-85-9 3-bromomethyl-1,2-benzisoxazole 

Downstream Products

• 1621019-18-8 3-(benzo[d]isoxazol-3-yl)-1-cyclohexylpyrrolidine-2,5-dione 
• 1621019-19-9 3-(benzo[d]isoxazol-3-yl)-1-(4-fluorophenyl)pyrrolidine-2,5-dione 
• 1621019-20-2 3-(benzo[d]isoxazol-3-yl)-1-(4-chlorophenyl)pyrrolidine-2,5-dione 
• 1621019-21-3 3-(benzo[d]isoxazol-3-yl)-1-(4-methoxyphenyl)pyrrolidine-2,5-dione 
• 1621019-22-4 3-(benzo[d]isoxazol-3-yl)-1-phenylpyrrolidine-2,5-dione 

Relevant articles and documents

Design, Synthesis, and Evaluation of Novel Benzo[ d]isoxazole Derivatives as Anticonvulsants by Selectively Blocking the Voltage-Gated Sodium Channel NaV1.1

Sodium channel blockers are important antiseizure drugs. Since the launch of phenobarbital in 1912, it has a development history of nearly 100 years. However, because of the confounding symptoms, complications, and complex intrinsic pathogenesis of epilepsy, the design and development of blockers specifically targeting sodium channels as antiseizure drugs are difficult and rarely reported. In this study, we designed and synthesized a series of novel benzo[d]isoxazole derivatives as anticonvulsants. Among them, the most potent Z-6b displayed high protection against the MES-induced seizures with an ED50 value of 20.5 mg/kg and a high protective index (TD50/ED50) of 10.3. In addition, Z-6b significantly inhibited NaV1.1 channels in patch-clamp experiments but almost did not inhibit NaV1.2, NaV1.3, and NaV1.6 channels. These findings strongly support the hypothesis that new benzo[d]isoxazole derivatives display anticonvulsant activity by selectively blocking voltage-gated sodium channel NaV1.1, which provides good alternatives for developing selective NaV1.1 channel blockers as antiseizure drugs in the future.

Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants

A series of 3-(benzo[d]isoxazol-3-yl)-N-substituted pyrrolidine-2, 5-dione (7a-7d, 8a-8d, 9a-9c) have been prepared and evaluated for their anticonvulsant activities. Preliminary anticonvulsant activity was performed using maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) tests after intraperitoneal (ip) injection into mice, which are the most widely employed models for early identification of anticonvulsant candidate. The acute neurological toxicity (NT) was determined applying rotorod test. The quantitative evaluation after oral administration in rats showed that the most active was 3-(benzo[d]isoxazol-3-yl)-1-(4-fluorophenyl) pyrrolidine-2, 5-dione (8a) with ED50 values of 14.90 mg/kg. Similarly the most potent in scPTZ was 3-(benzo[d]isoxazol-3-yl)-1-cyclohexylpyrrolidine-2, 5-dione (7d) with ED50 values of 42.30 mg/kg. These molecules were more potent and less neurotoxic than phenytoin and ethosuximide which were used as reference antiepileptic drugs.

Novel base-induced rearrangements of α- and N-halo derivatives of S-ary-S-[(1,2-benzisoxazol-3-yl)methyl]sulfoximides to the corresponding N-sulfinylimines

-